Global Vaccine Action Plan

Global Vaccine Action Plan
Name	Global Vaccine Action Plan
Caption	Global Vaccine Action Plan logo
Type	International public health strategy
Founded	2012
Founders	World Health Organization; United Nations partners
Area served	Worldwide
Focus	Immunization; vaccine access; disease elimination

Global Vaccine Action Plan The Global Vaccine Action Plan (GVAP) was a decadal strategy launched to accelerate immunization coverage, disease control, and vaccine equity across World Health Assembly member states. Developed under the stewardship of the World Health Organization in partnership with United Nations Children's Fund, Gavi, the Vaccine Alliance, and other global health institutions, the GVAP sought to coordinate efforts among national ministries, philanthropic organizations, and technical agencies. The initiative translated commitments from the 2010 Global Summit on Immunization and high-level resolutions into operational targets, emphasizing eradication, elimination, and routine immunization strengthening.

Background and development

GVAP originated from discussions at the World Health Assembly and inputs from the Strategic Advisory Group of Experts on Immunization and the Global Immunization Vision and Strategy 2006–2015. Key stakeholders included Bill & Melinda Gates Foundation, Pan American Health Organization, European Medicines Agency, Centers for Disease Control and Prevention, and national bodies such as Ministry of Health (United Kingdom), Ministry of Health and Family Welfare (India), and Centers for Disease Control and Prevention (United States). The plan was shaped by experiences from campaigns against smallpox eradication, poliomyelitis eradication efforts, and regional elimination initiatives like the Americas polio elimination program and the Measles & Rubella Initiative. Consultations drew representatives from academic institutions such as Johns Hopkins Bloomberg School of Public Health, London School of Hygiene & Tropical Medicine, and Institut Pasteur to integrate evidence from immunology, vaccine safety, and health systems research.

Goals and strategic objectives

GVAP articulated global goals aligned with resolutions from the United Nations General Assembly and targets endorsed by the Millennium Development Goals successor discussions. Primary objectives included sustaining the eradication of wild poliovirus, achieving regional elimination of measles, interrupting transmission of rubella, and increasing routine immunization coverage to reach children in underserved areas identified by World Bank poverty mapping and United Nations Development Programme indicators. Strategic objectives emphasized strengthening national immunization systems in line with recommendations from the Global Fund to Fight AIDS, Tuberculosis and Malaria, improving vaccine research and development linked to European Commission programs, and enhancing regulatory systems working with the International Federation of Pharmaceutical Manufacturers & Associations.

Implementation and governance

Governance structures combined leadership from World Health Organization and United Nations Children's Fund with operational support from Gavi, the Vaccine Alliance and coordination through the Global Vaccine Action Plan Secretariat. Implementation mechanisms relied on regional bodies like Pan American Health Organization, WHO Regional Office for Africa, WHO Regional Office for the Eastern Mediterranean, WHO Regional Office for Europe, WHO Regional Office for South-East Asia, and WHO Western Pacific Regional Office. National immunization technical advisory groups, modeled after the Strategic Advisory Group of Experts on Immunization, coordinated ministry-level implementation alongside donor coordination platforms such as those used by United States Agency for International Development and Foreign, Commonwealth & Development Office. Financing blended domestic budgets, Gavi support, and contributions from philanthropic donors including Rockefeller Foundation and Wellcome Trust.

Regional and country-level adoption

Adoption varied across regions, with early uptake in countries participating in regional elimination agendas like Pan American Health Organization members and European Region of WHO states pursuing measles elimination. Countries with large-scale programs included India, Nigeria, Pakistan, Indonesia, and Bangladesh where national immunization drives interfaced with initiatives such as Polio Eradication Initiative and routine services supported by United States Agency for International Development grants. Middle-income countries engaged through mechanisms described by the Organization for Economic Co-operation and Development and multilateral banks including the Asian Development Bank and African Development Bank for co-financing. Subnational strategies drew on models from the Expanded Programme on Immunization and innovations trialed in settings like Rwanda and Ethiopia.

Monitoring, evaluation, and impact

Monitoring frameworks aligned with indicators used by the Global Polio Eradication Initiative, Measles & Rubella Initiative, and the Sustainable Development Goals immunization targets. Data systems incorporated inputs from surveillance networks coordinated by WHO and laboratories within the Global Measles and Rubella Laboratory Network and the Global Polio Laboratory Network. Evaluation employed methods from institutions such as Institute for Health Metrics and Evaluation and RAND Corporation to assess coverage, equity, and burden reduction. Reported impacts included progress in reducing vaccine-preventable mortality tracked against World Bank health indicators and measurable declines in cases of measles and rubella in various regions, though mixed results were observed for reaching zero-dose children identified in UNICEF analyses.

Challenges and criticisms

Critics pointed to uneven implementation, funding shortfalls flagged by Gavi and the World Health Organization financing reviews, and governance complexities involving multiple multilateral actors like World Bank and bilateral donors such as United States Agency for International Development and Department for International Development (UK). Operational challenges included supply chain constraints documented by United Nations Development Programme, vaccine hesitancy studied by scholars at Harvard T.H. Chan School of Public Health and University of Oxford, and surveillance gaps in conflict-affected settings exemplified by crises in Syria, Yemen, and parts of Democratic Republic of the Congo. Evaluators from Independent Oversight Advisory Committee-type mechanisms and think tanks like Chatham House highlighted shortcomings in accountability and measurable equity outcomes.

Legacy and successor initiatives

GVAP informed successor frameworks incorporated into WHO’s broader immunization agendas and the Immunization Agenda 2030 developed with partners such as Gavi, the Vaccine Alliance, UNICEF, Bill & Melinda Gates Foundation, and regional offices. Lessons learned influenced program design in subsequent initiatives including pandemic preparedness dialogues at the World Health Assembly and partnerships among research entities like Coalition for Epidemic Preparedness Innovations and regulatory networks such as the International Coalition of Medicines Regulatory Authorities. GVAP’s emphasis on multisectoral collaboration continues to shape policy within institutions like the Global Fund and national ministries, and its metrics contributed to ongoing tracking by the Sustainable Development Solutions Network and global health observatories.

Category:Global health Category:Vaccination